Clinical Trial Update: An Open Label Extension Study in Subjects With Fragile X Syndrome [Phase 3]

View source ↗

Summary

An open-label extension study in Fragile X syndrome (Phase 3) has been terminated; the document provides the current status of the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Snippet

Sponsor: Seaside Therapeutics, Inc. | Conditions: Fragile X Syndrome | Phase 3 | Status: TERMINATED